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Abstract 
Background: DNA methylation is important for the maintenance of the silent state of genes on the inactive X 
chromosome (Xi). Here, we screened for siRNAs and chemicals that reactivate an Xi-linked reporter in the presence of 
5-aza-2′-deoxycytidine (5-aza-2′-dC), an inhibitor of DNA methyltransferase 1, at a concentration that, on its own, is 
not sufficient for Xi-reactivation.
Results: We found that inhibition of ribonucleotide reductase (RNR) induced expression of the reporter. RNR inhibi-
tion potentiated the effect of 5-aza-2′-dC by enhancing its DNA incorporation, thereby decreasing DNA methylation 
levels genome-wide. Since both 5-aza-2′-dC and RNR-inhibitors are used in the treatment of hematological malig-
nancies, we treated myeloid leukemia cell lines with 5-aza-2′-dC and the RNR-inhibitor hydroxyurea, and observed 
synergistic inhibition of cell growth and a decrease in genome-wide DNA methylation.
Conclusions: Taken together, our study identifies a drug combination that enhances DNA demethylation by altering 
nucleotide metabolism. This demonstrates that Xi-reactivation assays can be used to optimize the epigenetic activity 
of drug combinations.
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Background
X chromosome inactivation (XCI) is a program of tran-
scriptional gene silencing that occurs on one of two 
X chromosomes in female mammalian cells to equal-
ize gene dosage of X-linked genes to male cells. The 
inactive X chromosome (Xi) is a striking example of 
developmentally regulated heterochromatin formation in 
mammals. XCI has served as paradigm for understanding 
factors with generalized roles in gene silencing genome-
wide such as DNA methylation and Polycomb protein-
mediated histone methylation [1–3]. The Xi is established 
early in female embryonic development through a 
series of stepwise molecular changes that cooperate to 
ensure stable chromosome-wide gene silencing. Once 
established, the Xi is inherited through all somatic cell 
divisions and adult life [1–3]. XCI is initiated by the 
upregulation of the long noncoding RNA Xist from the 
maternal or paternal X chromosome early in embryonic 
development [1–3]. Xist coats the X chromosome from 
which it is expressed and initiates a cascade of events 
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including exclusion of RNA polymerase II, changes in 
histone marks, and recruitment of structural chromo-
some proteins [1–3]. Accumulation of the histone variant 
macroH2A1 and gain of CpG island methylation char-
acterize the transition to the maintenance phase of XCI, 
which is marked by resistance to X chromosome reacti-
vation (XCR) upon deletion of Xist [4–9]. Thus, Xist is 
absolutely required for the initiation of XCI, but later is 
largely dispensable for the maintenance of the Xi, due to 
the presence of various other repressive chromatin marks 
[8, 9]. Notably, complete XCR is induced in vivo during 
pre-implantation and germ line development and in vitro 
by reversing cellular identity to the pluripotent state 
[10–13].
Despite the observation that many repressive chroma-
tin factors are implicated in Xi establishment and main-
tenance, interference with DNA methylation has thus far 
shown the largest effect on eliciting loss of gene silenc-
ing on the Xi [5, 9, 14]. It is therefore thought that DNA 
methylation may uniquely ‘lock-in’ the silenced state 
and execute a greater influence on the robust nature of 
Xi maintenance than other repressive regulatory mecha-
nisms [9]. DNA methylation concentrates on CpG islands 
in the course of XCI with redistribution away from intra-
genic and intronic CpGs relative to the active X chro-
mosome [5, 7, 15, 16, 17]. CpG island methylation on 
the Xi is established by the de novo methyltransferase 
DNMT3B and is subsequently propagated by the main-
tenance methyltransferase DNMT1 [5, 9, 15]. Interfer-
ence with DNA methylation by deletion of Dnmt1 or 
treatment with 5-aza-2′-deoxycytidine (5-aza-2′-dC, 
also called decitabine) has been shown to induce the 
reactivation of an Xi-linked reporter gene and endog-
enous X-linked genes in a proportion of female somatic 
cells [9]. 5-aza-2′-dC is a deoxycytidine analog that upon 
phosphorylation incorporates into DNA and irreversibly 
inhibits DNMT1 [18]. Subsequent rounds of DNA repli-
cation therefore lead to passive DNA demethylation due 
to the absence of DNMT1 activity [19]. Together these 
findings indicate that Xi reporter systems permit the 
functional analysis of gene silencing, and that in addition 
to DNA methylation various other mechanisms contrib-
ute to Xi silencing. Therefore, XCI is an attractive model 
system to probe therapeutic approaches to the reactiva-
tion of silenced genes.
In the field of cancer biology, there is growing apprecia-
tion that abnormalities in histone modification and DNA 
methylation pathways can drive tumorigenesis across 
many cancer types and there is promise for improved 
therapies aimed at reversal of gene silencing [20]. In this 
study, we bridge the study of the Xi with the development 
of strategies to more efficiently demethylate and reacti-
vate silenced genes. 5-aza-2′-dC is used clinically in the 
setting of hematologic malignancies with the rationale 
of reactivating silenced genes [19]. The drug is currently 
approved for the treatment of myelodysplastic syn-
drome (MDS) and acute myeloid leukemia (AML) [20]. 
Several studies have confirmed that 5-aza-2′-dC at low 
doses elicits genome-wide DNA demethylation in AML 
patient samples [21–23]. One approach to increase the 
epigenetic activity of 5-aza-2′-dC in myeloid malignancy 
is to use it in combination with other agents known to 
elicit reactivation of silenced genes, such as histone dea-
cetylase inhibitors [20]. Notably, for the Xi, such co-treat-
ment approaches increase the rate of XCR in cell culture 
systems [9]. The similar efficacy of 5-aza-2′-dC alone or 
in combination with other chromatin-modifying agents 
in Xi-linked genes and in myeloid leukemia supports the 
translation of findings from X-chromosome inactivation 
to epigenetic cancer therapies.
Here, we set out to find additional pathways that in 
combination with 5-aza-2′-dC, elicit XCR. Specifi-
cally, we applied high-throughput siRNA and chemi-
cal screening to identify factors that could reactivate a 
silent reporter transgene that is specifically located on 
the Xi. Our screen employed treatment with a low dose 
of 5-aza-2′-dC to sensitize somatic cells for DNA dem-
ethylation and XCR, which on its own is not sufficient to 
induce these effects. We identified that inhibition of the 
ribonucleotide reductase protein complex significantly 
enhances the DNA demethylation action of 5-aza-2′-dC 
and hence the activity of the Xi-reporter. We characterize 
the mechanism of action as increasing DNA incorpora-
tion of 5-aza-2′-dC and thus its demethylating activity. 
While our approach initially centered on the Xi, we found 
a pathway that altered DNA methylation levels genome-
wide. Our study therefore demonstrates that assays of 
XCR can be adapted to optimize the epigenetic activity of 
a DNA demethylating drug combination.
Results and discussion
An siRNA screen for XCR in the presence of a low 
5‑aza‑2′‑dC dose identifies the ribonucleotide reductase 
pathway
Previous work from our lab has shown that an Xi-linked, 
CAG promoter-driven luciferase transgene in the Hprt 
locus (Xi-luciferase) is a sensitive reporter of gene silenc-
ing on the Xi when tested in primary mouse embryonic 
fibroblasts (MEFs) [24]. Our Xi-luciferase MEFs faith-
fully inactivate the luciferase-bearing X chromosome 
in female embryonic development rather than under-
going random XCI because an Xist deletion on the 
other X chromosome forces XCI on the chromosome 
carrying the wild-type Xist allele [25] (Fig.  1a). The Xi-
luciferase gene body and promoter are highly methyl-
ated at the DNA level and Xi-luciferase reporter MEFs 
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increase luciferase activity in a dose-dependent fashion 
in response to 5-aza-2′-dC treatment [24]. Here, we used 
Xi-luciferase reporter MEFs to screen for gene knock-
downs or chemicals that could elicit XCR.
In order to perform a high-throughput screen for XCR, 
we established an siRNA knockdown assay in 384-well 
format, with each individual siRNA tested in a single 
well. As positive control, we chose knockdown of Dnmt1 
since interference with Dnmt1 either by knockout or 
5-aza-2′-dC treatment has previously been described to 
elicit XCR in MEFs [9, 24]. Initially, we tested increas-
ing concentrations of 5-aza-2′-dC in combination with 
Dnmt1 knockdown to determine a 5-aza-2′-dC con-
centration for which the depletion of Dnmt1 by siRNAs 
yielded robust reporter reactivation, but where 5-aza-
2′-dC treatment alone does not elicit reactivation. Our 
titration experiment demonstrated that the combina-
tion of 5-aza-2′-dC at a concentration ranging from 0.1 
to 0.2  μM, along with siDnmt1 treatment, enhanced 
luciferase activity in the 384-well format. Importantly, 
5-aza-2′-dC treatment in this concentration range or 
knockdown of Dnmt1 alone did not induce a significant 
difference in luciferase signal compared to untreated 
wells (Additional file  1: Figure  S1A). The requirement 
for 5-aza-2′-dC co-treatment with Dnmt1 knockdown to 
detect XCR likely reflects that Dnmt1 knockdown alone 
does not lead to sufficient levels of XCR detected in the 
small 384-well format assay. By comparison, a higher 
dose of 5-aza-2′-dC (1 μM) elicited strong reactivation 
of the Xi-linked luciferase reporter on its own that was 
not as dramatically enhanced by siDnmt1 treatment 
(Additional file 1: Figure S1A). Thus, a low dose of 5-aza-
2′-dC has a sensitizing effect on eliciting XCR by Dnmt1 
knockdown. The interaction of 5-aza-2′-dC with other 
Xi maintenance factors indicates a similar sensitizing 
effect with respect to XCR. For instance, the knock-
down of the candidate Xi-maintenance factor Atf7ip or 
deletion of Xist produces a low rate of XCR that is sig-
nificantly boosted by the addition of 5-aza-2′-dC [9, 24]. 
Therefore, we extended the low concentration 5-aza-
2′-dC treatment (0.2  μM) to the entire genome-wide 
siRNA screen with the rationale that knockdown of 
other chromatin-modifying factors may require concur-
rent DNA demethylation to produce strong Xi-luciferase 
reporter reactivation.
We performed a genome-wide mouse siRNA screen 
with 51,150 siRNAs against 21,114 genes on 153 384-well 
plates (see “Methods” section for details on the library 
used) in duplicate using female Xi-linked luciferase 
reporter MEFs in the presence of low 5-aza-2′-dC. We 
measured luciferase levels 72 h after siRNA transfection 
(Fig. 1b). To eliminate batch effects, we normalized lumi-
nescence data by 384-well plate, and then analyzed the 
data by prioritizing gene hits with multiple active siRNAs 
by redundant siRNA activity (RSA) analysis [26] (Fig. 1c, 
Additional file 2: Figure S2). Notably, Dnmt1 was the top 
hit in our genome-wide screen, which provided internal 
validation of the method (Fig. 1c). Further support came 
from another hit, identified as Atf7ip, which our group 
recently reported as a maintenance factor in XCI [24]. As 
with other previously described maintenance factors, we 
found that the Xi-luciferase signal in response to knock-
down of Atf7ip was greatly increased by low 5-aza-2′-dC 
(0.2 μM) co-treatment [24]. Identification of Atf7ip in the 
screen supports the strategy of 5-aza-2′-dC co-treatment 
to unmask functional contribution of Xi-maintenance 
factors.
To select novel hits, we chose the top 54 genes from 
the RSA analysis with at least two unique active siRNAs 
inducing an increase in luciferase levels in the 384-well 
(See figure on previous page.)
Fig. 1 High-throughput siRNA and chemical screens identify RRM2 depletion and resveratrol as mediators of XCR. a Schematic of the X chromo-
somes in female reporter MEFs carrying the luciferase reporter transgene in the Hprt locus specifically on the Xi. The Xist deletion on one of the 
chromosomes skews X-inactivation to the wild-type Xist-bearing X chromosome. b Diagram of the screening workflow. siRNAs from the mouse 
genome-wide library and selected chemical libraries were assayed in 384-well plates containing a column of positive and negative controls. 
Xi-luciferase reporter MEFs were added and incubated for 72 h in the presence of 5-aza-2′-dC (0.2 μM) prior to a luciferase assay. c Gene activity dis-
tribution plot ranked by the –log of the p-value obtained with the redundant siRNA activity (RSA) assay from duplicate genome-wide siRNA screens 
following transformation of the luminescence activity values into robust z-scores. The top validated hits, Dnmt1, Atf7ip, and Rrm2, are labeled. d (i) 
Graph depicting Xi-luciferase reporter reactivation upon knockdown of Rrm2 with the three siRNAs (A, B, C) obtained from the genome-wide library 
in the presence or absence of 5-aza-2′-dC (0.2 μM) in the 12-well format. Luminescence was measured 72 h after the start of the treatment. Error 
bars indicate standard deviation of luminescence unit values from three individual wells with a given treatment in one experiment. (ii) RT-qPCR for 
RNA levels of Rrm2 normalized to siGFP control and Gapdh expression. RNA was harvested in parallel to luciferase assays shown in (i). Error bars indi-
cate standard deviation from three measurements in one experiment. e Activity of chemicals in the chemical screen in the presence of 5-aza-2′-dC 
(0.2 μM), ranked by luminescence unit with the value corresponding to resveratrol designated. f Xi-luciferase reporter assay as described in (di) 
titrating the resveratrol concentration with or without 5-aza-2′-dC (0.2 μM). g Xi-luciferase reporter assay as in (di) titrating hydroxyurea (HU) with 
or without (untreated) 5-aza-2′-dC (0.2 μM). The result for resveratrol treatment in the same experiment is given for comparison. h (i) Xi-luciferase 
reporter assay as in (di) comparing the consequences of 0.2 μM 5-aza-2′-dC treatment and siRNA-mediated knockdown of Dnmt1 to elicit reporter 
reactivation by 20 μM resveratrol. (ii) RT-qPCR for Dnmt1 RNA levels normalized to siGFP control and Gapdh expression in the same experiment as (i)
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screen, omitting genes we deemed irrelevant such as 
those for olfactory receptors, and retested the active 
siRNAs sequences from the library (Additional file  3: 
Table  S1). Several of these siRNAs showed reproduc-
ible increases in luciferase activity in the validation assay 
(Additional file  4: Figure  S3). We decided to focus on 
Rrm2 as a hit since one siRNA against it had produced 
the next highest level of luciferase activity in the valida-
tion assay after the siRNAs targeting Atf7ip or Dnmt1. 
Follow-up assays with a greater number of starting cells 
demonstrated an increase in luciferase activity for each 
of our three different siRNAs against the ribonucleotide 
reductase (RNR) M2 subunit gene (Rrm2) (Fig. 1d). The 
luminescence generated with siRrm2 treatment was in 
proportion to individual extent of Rrm2 knockdown, sug-
gesting specificity of Rrm2 targeting for the XCR effect 
(Fig. 1d).
As part of the RNR enzyme complex, RRM2 catalyzes 
the conversion of ribonucleoside 5′-disphosphates to 
their 2′-deoxyribonucleoside form in the rate-limiting 
step of de novo dNTP biosynthesis [27]. The RRM2 subu-
nit, which was identified in this siRNA screen, is specifi-
cally upregulated at S phase of cell cycle and is necessary 
for the activity of the RNR complex [27]. Since we iden-
tified siRrm2 in combination with 5-aza-2′-dC (0.2 μM) 
in the genome-wide screen, we next asked if knockdown 
of Rrm2 could also elicit XCR in the absence of 5-aza-
2′-dC, since interference with Atf7ip or Xist produces 
a low rate of XCR that is significantly boosted by the 
addition of 5-aza-2′-dC [9, 24]. However, unlike previ-
ously described Xi-maintenance factors, we did not find 
that siRrm2 produced luciferase activity in the absence 
of 5-aza-2′-dC (Fig.  1d). These results were reproduced 
with an Xi-linked fluorescent reporter (Additional file 5: 
Figure S4B/C) [9]. We conclude that low doses of 5-aza-
2′-dC are necessary for the XCR effect of siRrm2 identi-
fied by our genome-wide screen for factors involved in 
the maintenance of Xi silencing.
Chemical inhibitors of ribonucleotide reductase elicit XCR 
in the presence of 5‑aza‑2′‑dC
We used a complimentary approach to further probe the 
pathways contributing to Xi maintenance by performing 
a companion screen analogous to the siRNA screen but 
instead using a collection of annotated chemicals (Fig. 1b, 
Additional file  6: Figure  S5A). In the screen, we found 
that resveratrol, a chemical agent known for mimicking 
cellular effects of caloric restriction, demonstrated the 
potential to activate the Xi-luciferase reporter (Fig.  1e) 
[28]. To validate the screening result, we tested the effect 
of various resveratrol concentrations on the Xi-luciferase 
reporter. The bell-shaped dose–response activity of res-
veratrol in combination with fixed, low concentration of 
5-aza-2′-dC (0.2 μM) indicated a maximal XCR activity 
at a concentration of 20  μM (Fig.  1f ). In order to con-
firm an XCR-specific effect, we tested whether the com-
bination of resveratrol with 5-aza-2′-dC could reactivate 
different Xi-linked reporters. We found that 20 μM res-
veratrol and 5-aza-2′-dC (0.2  μM) together could also 
reactivate two fluorescent reporters including the CAG-
driven H2B citrine transgene within the Hprt locus and 
a distal CAG-driven GFP transgene (Additional file  6: 
Figure S4) [9, 24]. As previously observed, the proportion 
of cells expressing the reporter differs for Xi-CAG-H2B-
citrine and Xi-GFP MEFs likely owing to different silenc-
ing requirements of the two loci on the Xi [24].
Resveratrol is a naturally-occurring polyphenolic mol-
ecule believed to have numerous direct intracellular 
protein targets [29]. It is described to mediate its meta-
bolic effects through direct and indirect activation of 
the histone deacetylase SIRT1 though no specific role in 
reversal of chromatin silencing or effects on the Xi has 
been described [30–32]. Of note, we did not find that 
knockdown of Sirt1 attenuated the ability of resveratrol 
with 5-aza-2′-dC to elicit Xi-luciferase reactivation (not 
shown). A further search for the cellular target of resvera-
trol in XCR led us to a study that described resveratrol as 
an inhibitor of RNR, the same enzyme complex that we 
identified as a hit in the genome-wide siRNA screen for 
XCR described above [33]. This link between our com-
plimentary screening approaches pointed to resveratrol’s 
role in XCR in the presence of 5-aza-2′-dC by means of 
RNR inhibition.
In order to further investigate whether RNR is the 
target of resveratrol in eliciting XCR, we tested a well-
characterized inhibitor of RNR, hydroxyurea (HU), 
and found that it also increased Xi-luciferase activity 
in the presence of a low dose of 5-aza-2′-dC (0.2  μM) 
(Fig. 1g). From the titration, HU had a maximum effect 
on Xi-luciferase reactivation at 50  and at 200  μM and 
a fading effect at 20 μM (Fig. 1g). HU was not detected 
from the chemical library because it was assayed at a 
screening concentration of 10 μM, which was probably 
insufficient concentration to detect activity. 50 μM HU 
treatment in combination with low 5-aza-2′-dC also 
induced reactivation of the Xi-linked GFP (Additional 
file 5: Figure S4B/C). We reasoned that if resveratrol and 
HU converge on inhibition of RNR, that the XCR effect of 
resveratrol and HU should require the co-treatment with 
5-aza-2′-dC as seen for the Rrm2 knockdown. Indeed, we 
found that similar to the siRrm2 condition, resveratrol 
and HU treatment demonstrated a complete dependence 
on low levels of 5-aza-2′-dC to elicit XCR (Fig.  1d/f/g, 
Additional file 5: Figure S4B/C). We conclude that RNR 
inhibition alone by these various means does not increase 
Xi-luciferase activity.
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Since the Xi-luciferase reporter assay is not reflec-
tive of cell number, we measured protein concentration 
in luciferase assay lysates to rule out variable cell num-
ber due to different treatments as an explanation for lack 
of Xi-reporter activation in the absence of 5-aza-2′-dC 
(Additional file 7: Figure S6A). Variations in protein lysate 
concentration were minor across all treatments, indicat-
ing RNR inhibition requires the presence of 5-aza-2′-dC to 
elicit its effect on XCR. The identification of chemicals with 
RNR-inhibiting activity added support to the XCR role of 
inhibiting this pathway in the presence of 5-aza-2′-dC.
We further investigated the relationship between 
5-aza-2′-dC and RNR inhibition in XCR by querying 
whether 5-aza-2′-dC can be replaced by knockdown 
of Dnmt1. In previous studies where 5-aza-2′-dC had 
a sensitizing effect towards XCR, the effect is attrib-
utable to interference with Dnmt1 [24]. For instance, 
5-aza-2′-dC treatment could be substituted by knock-
down of Dnmt1 to elicit synergistic XCR by Atf7ip 
knockdown [24]. Contrary to these prior findings, we 
found that Dnmt1 depletion by siRNAs did not replace 
the contribution of 5-aza-2′-dC to XCR induced by 
RNR-inhibition via resveratrol (Fig.  1h). Together, 
these findings suggest a mechanism of action whereby 
RNR inhibition specifically affects the action of cyti-
dine analog 5-aza-2′-dC.
RNR inhibition increases incorporation of 5‑aza‑2′‑dC 
into DNA
Next, we sought to understand how RRM2 inhibition 
interacts with low amounts of 5-aza-2′-dC to elicit XCR. 
The pool of dNTPs in the nucleus is tightly regulated and 
studies have speculated that RNR inhibition can increase 
the likelihood of nucleoside analog DNA incorporation 
by reducing the pools of endogenous nucleotide concen-
trations [27, 34]. Accordingly, we postulated that RRM2 
inhibition may increase 5-aza-2′-dCTP concentration in 
the nucleus relative to the endogenous dCTP pool, lead-
ing to more 5-aza-2′-dCTP DNA incorporation (Fig. 2a). 
Higher rates of 5-aza-2′-dC incorporation into DNA sub-
sequently could lead to greater DNA demethylation and 
XCR (Fig. 2a).
Consistent with this model, we observed that knock-
down of Rrm2 or resveratrol treatment reproducibly 
increased the amount of tritiated 5-aza-2′-dC incorpo-
rated into DNA approximately by two-fold (Fig.  2b). 
We further tested the role of the ratio of 5-aza-2′-dCTP 
to endogenous dCTP by the converse manipulation of 
increasing dCTP relative to 5-aza-2′-dC. This experi-
ment was performed by adding increasing concentrations 
of deoxycytidine (dC) into media, which is metabolized 
to dCTP within the cell, in the presence of 5-aza-2′-dC 
with resveratrol treatment (Fig. 2c) or Rrm2 knockdown 
(Fig. 2d). Importantly, dC does not require the action of 
RNR for DNA incorporation. Our expectation was that 
an increase in dCTP levels in the cell would reduce the 
incorporation of 5-aza-2′-dC into the DNA, and there-
fore reduce the reactivation of the Xi-linked luciferase 
reporter. As expected, the luciferase signal decreased in 
a dose-dependent fashion when exogenous deoxycytidine 
was supplied in the media (Fig. 2c/d). The loss of the Xi-
reporter reactivation is consistent with the notion that 
the relative nuclear concentration of 5-aza-2′-dCTP to 
dCTP is shifted by the addition of an exogenous nucleo-
tide substrate to reduce the effective concentration of the 
5-aza-2′-dC analog (Fig. 2c/d).
An alternate explanation for the observed decrease in 
luciferase signal upon addition of dC is a reduction in 
cell number. To rule out possible nucleotide treatment-
dependent cell growth effects, we confirmed that pro-
tein concentrations in lysates were similar for the various 
treatment conditions (Additional file  7: Figure S6B/C). 
Furthermore, we used uridine as a control because it is 
a nontoxic precursor of pyrimidine synthesis that, like 
deoxycytidine, can be taken up by cells and used as a 
substrate via the nucleoside salvage synthetic pathway 
(Fig.  2c/d) [35]. However, unlike deoxycytidine, uridine 
requires reduction by RNR in order to contribute to 
dNTP pools [35]. Increasing levels of uridine did not alter 
Xi-luciferase levels and thereby XCR in the presence of 
5-aza-2′-dC with Rrm2 knockdown and resveratrol treat-
ment, respectively, compared to control (Fig. 2c/d, Addi-
tional file 7: Figure S6B/C). These results support the role 
of deoxycytidine in reversing the XCR effect downstream 
of RNR.
In summary, RRM2/RNR inhibition was identified in 
the XCR screen because it augmented 5-aza-2′-dC DNA 
incorporation. This mechanism is consistent with the 
observation that RNR inhibition alone, i.e. in the absence 
of 5-aza-2′-dC, did not produce measurable Xi-reporter 
reactivation in prior assays.
RRM2 inhibition enhances genome‑wide demethylation 
caused by 5‑aza‑2′‑dC in MEFs
If RRM2 inhibition potentiates low dose 5-aza-2′-dC 
action to increase XCR by increasing the incorporation 
of 5-aza-2′-dC, then DNA methylation levels in cells 
treated with a low dose of 5-aza-2′-dC with RRM2 inhi-
bition should approximate those of cells treated with a 
high dose of 5-aza-2′-dC. We investigated DNA methyla-
tion patterns at genome-scale by reduced representation 
bisulfite sequencing (RRBS) [36]. Specifically, MEFs were 
treated with siRrm2 or resveratrol alone, low or high 
doses of 5-aza-2′-dC, and combinations of siRrm2 or res-
veratrol with a low dose of 5-aza-2′-dC (Fig. 3, Additional 
file 8: Figure S7, Additional file 9: Figure S8).
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As expected, based on global methylation averages, 
hierarchical clustering, and methylation distributions, 
the treatment of MEFs with a low dose of 5-aza-2′-dC 
(0.2  μM) induced a smaller reduction in the level of 
genome-wide methylation than the high dose of 5-aza-
2′-dC (10.0  μM), which resulted in marked demeth-
ylation compared to control samples (Fig.  3a, b, d, 
Additional file  8: Figure  S7C/D). We found that treat-
ment with siRrm2 or resveratrol alone (without 5-aza-
2′-dC) marginally increased global DNA methylation 
levels compared to untreated samples (Fig.  3a, b, d, 
Additional file  8: Figure  S7C/D). Notably, the combina-
tion of Rrm2 knockdown or resveratrol with the low 
dose 5-aza-2′-dC reduced global methylation to a similar 
extent as the high dose 5-aza-2′-dC treatment (Fig. 3a, b, 
d, Additional file 8: Figure S7C/D). These effects on the 
methylation profile were similar for autosomes and the X 
chromosome at the global scale (Fig. 3b, Additional file 9: 
Figure  S8A) as well as on promoters and CpG islands 
(Additional file 8: Fig. S7A, Additional file 9: Figure S8B). 
These findings are consistent with a genome-wide effect 
on DNA methylation rather than an Xi-specific mecha-
nism, owing to increased DNA incorporation of 5-aza-
2′-dC under RRM2 inhibition conditions. We observed 
that CpGs with the highest levels of methylation in the 
control samples showed the most dramatic 5-aza-2′-dC-
induced demethylation (Fig.  3c, Additional file  8: Fig-
ure S7B). For CpGs with lower methylation levels in the 
untreated conditions, demethylation due to 5-aza-2′-dC 
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Fig. 2 Inhibition of RNR enhances DNA incorporation of 5-aza-2′-dC to elicit XCR. a Illustration of model in which (1) inhibition of ribonucleotide 
reductase (RNR) by various means leads to (2) increased relative dCTP utilization for DNA synthesis from salvage pathways which are supplemented 
with exogenous 5-aza-2′-dC. (3) DNMT1 inhibition occurs upon binding to DNA-incorporated 5-aza-2′-dC leading to (4) increased loss of DNA 
methylation with successive cell divisions. b Quantification of 3H-5-aza-2′-dC (3H-Decitabine) incorporation into genomic DNA upon either resvera-
trol treatment or Rrm2 knockdown for 48 h. Genomic DNA was isolated and an equal volume measured for 3H-Decitabine incorporation (disin-
tegrations per minute, DPM), then normalized to the amount of DNA loaded (μg). Error bars indicate standard deviation from three independent 
treatment wells. Asterisks indicate p < 0.01 by Student’s T-test. c Xi-luciferase reactivation assay as in Fig. 1di in the presence of 0.2 μM 5-aza-2′-dC 
and 20 μM resveratrol and increasing concentrations of deoxycytidine (dC) or uridine. ALU represents luminescence unit values. d As in c except 
with siRrm2 in the place of resveratrol
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Additional file 8: Figure S7B). We believe that the greater 
apparent effect in highly methylated regions does not 
represent a predilection of 5-aza-2′-dC for highly meth-
ylated regions, as has been previously suggested  [21], 
but rather that the random incorporation of 5-aza-2′-dC 
disproportionately affects the methylation estimates of 
highly methylated sites.
We also extracted the available methylation data for 
the Xi-linked luciferase reporter gene to determine 
whether the methylation levels correlated with the 
extent of Xi-luciferase reactivation in the various con-
ditions. We found that CpG sites within the luciferase 
reporter gene followed the genome-wide methyla-
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Fig. 3 RNR inhibition increases 5-aza-2′-dC-mediated genome-wide DNA demethylation in MEFs. a Bar chart displaying average genome-wide 
CpG methylation levels for the indicated 72 h treatments filtered for CpGs with at least 5X sequencing coverage by RRBS across all samples. Label 
color reflects the various treatment groups. Subscripts (A and B) indicate replicates where applicable. Treatment concentrations are: LowAza (5-aza-
2′-dC 0.2 μM), HighAza (5-aza-2′-dC 10.0 μM), and Resv (resveratrol 20 μM). b Heat map of unsupervised hierarchical clustering of DNA methylation 
levels for all autosomal CpGs assayed by RRBS in MEFs treated with the indicated chemicals for 72 h as in a with at least 5X sequencing coverage 
across all samples. A methylation level of 1 indicates 100 % methylation, while 0 represents complete absence of methylation. c Heat maps as in b 
but for subsets of autosomal CpG sites partitioned into four groups representing different DNA methylation levels in the untreated control samples; 
(i) 0.75–1.0, (ii) 0.50–0.75, (iii) 0.25–0.50, and (iv) 0–0.25. In each case, the combination of RNR inhibition with 0.2 μM 5-aza-2′-dC clusters away from 
all other samples, but together with the high dose of 5-aza-2′-dC, and is more demethylated. d Histograms display DNA methylation distributions 
for all autosomal CpGs as in b for indicated treatments and replicates. Data for additional replicates can be found in Additional file 8: Figure S7C/D
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together with RNR inhibition, by either Rrm2 knock-
down or resveratrol, induced similar demethylation 
as the high dose of 5-aza-2′-dC (Additional file  10: 
Figure  S9). The concordant behavior of Xi-luciferase 
reporter CpG sites supports the conclusion that the 
augmentation of DNA incorporation of 5-aza-2′-dC 
describes the Rrm2 result in our Xi-reporter reactiva-
tion screen.
Taken together, our genome-wide methylation 
analysis for low dose 5-aza-2′-dC with RRM2 inhibi-
tion supports the idea that RRM2 inhibition increases 
the effective concentration of 5-aza-2′-dC and thereby 
its DNA incorporation, leading to global DNA 
demethylation.
Hydroxyurea and 5‑aza‑2′‑dC synergistically 
inhibit myeloid leukemia cell line proliferation in a 
dose‑dependent fashion
Given that RRM2 inhibition increases DNA incorporation 
of 5-aza-2′-dC, we next applied the combination of RRM2 
inhibition and 5-aza-2′-dC to a disease model in which 
5-aza-2′-dC has therapeutic relevance. 5-aza-2′-dC is an 
FDA-approved drug and commonly used off-label in the 
setting of acute myeloid leukemia (AML) [20]. Therefore, 
we tested the drug combination in four myeloid leukemia 
cell lines (THP1, U937, K562, HL60) (Fig.  4, Additional 
file  11: Figure S10). We hypothesized that, since RRM2 
inhibition increased DNA incorporation of 5-aza-2′-dC, 
the combination of RRM2 inhibition with 5-aza-2′-dC 
a
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Fig. 4 Hydroxyurea and 5-aza-2′-dC treatment of myeloid leukemia cell lines. a Dose–response curves measuring viable K562 cells using the 
Cell-Titer Glow Assay. Chemical treatments were performed with HU or 5-aza-2′-dC (Aza) alone or in combination at a fixed concentration ratio 
of 4000:1 HU:Aza (based on individual IC50 values). Red lines indicate concentrations assayed in the subsequent RRBS analysis displayed in c. The 
accompanying table depicts the Chow-Talalay analysis of the Combination Index (CI) at the given treatment combination concentrations. CI values 
<1.0 indicates synergy, 1= additive effect, and >1.0 antagonism of the combination drug effect. b As in a except dose–response curves for HL60 
cells using a fixed concentration ratio of 150:1 HU:Aza in the combined treatments. c Heat map showing an unsupervised hierarchical clustering of 
X chromosome CpG methylation levels in K562 cells treated with the indicated chemicals for 72 h. Only those CpGs with greater than 0.75 methyla-
tion level in the DMSO-treated samples are displayed, as these are the CpGs most dramatically affected by 5-aza-2′-dC treatment (see Fig. 3). CpGs 
were filtered for at least 10× sequencing coverage across all samples. DNA methylation levels were profiled for the treatments with the HU/aza 
concentration combinations indicated with red lines in a (labeled Low, Mid, High). In addition, we treated cells with either 5-aza-2′-dC or HU at the 
respective concentrations (Low HU (0.16 mM), Mid HU (0.4 mM), High HU (0.80 mM), and Low Aza (0.04 μM), Mid Aza (0.1 μM), High Aza (0.2 μM)). 
Aza was resuspended in DMSO, thus DMSO only controls are matched to volume of Aza added in corresponding Aza samples. d Flow cytometry 
analysis of propidium iodide-stained K562 cells treated with low and high HU concentrations as described in c compared to low or high DMSO 
control treatment
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could improve the therapeutic index of 5-aza-2′-dC, 
allowing lower doses to maximize demethylation activity 
with fewer cytotoxic off-target effects. We chose to use 
HU as the form of RRM2 inhibition because it also is an 
FDA-approved agent commonly used off-label for cyto-
reductive purposes, also in the setting of AML [37].
To assess the effect of combining HU and 5-aza-2′-dC 
on myeloid leukemia cell line proliferation, we applied a 
luminescence-based cell viability assay that linearly scales 
with cell number and titered HU and 5-aza-2′-dC indi-
vidually to determine IC50 values for each cell line (Addi-
tional file 11: Figure S10A). For 5-aza-2′-dC, IC50 values 
were difficult to approximate given a plateau in cell pro-
liferation changes at higher concentrations (not shown). 
Thus we chose the 5-aza-2′-dC concentration correspond-
ing to halfway to the point of plateau effect. We then 
combined HU and 5-aza-2′-dC at fixed ratios, empirically 
determined for each of the four myeloid leukemia cell lines 
(Fig.  4a/b, Additional file  11: Figure S10B/C). In each of 
the four cell lines tested, the combination treatment inhib-
ited cell proliferation more than either treatment alone. 
In order to make a quantitative determination of the drug 
interaction, we calculated Chou-Talalay Combination 
Indices (CI) where CI <1, =1, >1 indicate synergism, addi-
tive effect, and antagonism, respectively [38]. The combi-
nation of HU and 5-aza-2′-dC demonstrated evidence of 
drug synergism across a range of fixed drug concentration 
ratios in the four cell lines tested (Fig.  4a, b, Additional 
file 11: Figure S10B/C). We repeated the drug treatments 
with K562 cells in a soft agar assay and confirmed the syn-
ergistic effect of HU and 5-aza-2′-dC on clonal cell expan-
sion (Additional file 11: Figure S10D). Consistent with the 
proliferation studies, the combination HU and 5-aza-2′-dC 
reduced colony formation to a greater extent compared 
to either treatment alone. Together, these results demon-
strate a synergistic interaction between HU and 5-aza-
2′-dC in the control of cell proliferation.
We next assessed whether DNA demethylation related 
to the synergistic drug effect observed. Specifically, we 
determined the DNA methylation profile of K562 cells 
treated at a low, mid, and high concentration of 5-aza-
2′-dC and HU at a fixed ratio by RRBS (Fig.  4c, Addi-
tional file 12: Figure S11). The low average genome-wide 
CpG methylation levels of approximately 35  % in K562 
cells with few highly methylated CpGs is consistent with 
a prior studies reporting overall global hypomethylation 
inherent to K562 cells (Additional file  12: Figure  S11, 
DMSO-treated control conditions) [39]. Nonetheless, 
treatment with a fixed ratio of low HU and 5-aza-2′-dC 
concentrations, that induced a synergistic effect on cell 
growth (Fig. 4a, low condition), reduced DNA methyla-
tion compared to the low 5-aza-2′-dC treatment alone 
(Fig. 4c). As expected, HU treatment alone did not alter 
DNA methylation levels (Fig. 4c). As with MEFs, filtering 
by CpGs that are highly methylated in control conditions 
best displayed the enhancing effect of low HU to low 
5-aza-2′-dC concentrations (Fig.  4c, Additional file  12: 
Figure S11A).
Unexpectedly, methylation levels did not appreciably 
decrease and even increased with the higher dose com-
binations of HU and 5-aza-2′-dC (mid and high treat-
ment combinations) (Fig.  4c). Particularly at the high 
concentration combination, HU addition almost com-
pletely blunted the effect of 5-aza-2′-dC on methylation 
(Fig. 4c, Additional file 12: Figure S11). We hypothesized 
that the differing effects of the low and high concentra-
tion combinations may be due to interference of cell cycle 
progression with increasing concentrations of HU, which 
in turn interferes with the incorporation of 5-aza-2′-dC 
into DNA during DNA replication. Accordingly, flow 
cytometry analysis revealed a significant cell-cycle arrest 
of K562 cells at the high HU concentration, but not at the 
low concentration (Fig. 4d).
Our data suggest that at lower concentrations, HU 
and 5-aza-2′-dC act synergistically on cell growth, at 
least partially via DNA demethylation, while at higher 
concentrations, direct effects on cell cycle progression 
inhibit cell growth not allowing DNA demethylation via 
5-aza-2′-dC, which is replication dependent. Regard-
less, these data indicate that the combination of HU and 
5-aza-2′-dC synergistically decreases cell proliferation of 
the four myeloid leukemia cell lines tested. Moreover, the 
mechanism of action of this synergistic drug combina-
tion changes in a dose-dependent fashion.
Conclusions
Using an Xi-linked luciferase reporter sensitized to reac-
tivate by low concentration 5-aza-2′-dC treatment, we 
screened genome-wide siRNA and chemical libraries for 
reactivation activity. We found that inhibition of the RRM2 
subunit of the ribonucleotide reductase enzyme increases 
rates of Xi-linked reporter reactivation. We attribute the 
effect of RRM2 inhibition on the Xi in MEFs to augmenta-
tion of 5-aza-2′-dC incorporation into DNA, which in turn 
induces increased genome-wide DNA demethylation in a 
pattern similar to a high dose 5-aza-2′-dC treatment alone. 
Moreover, treatment of myeloid leukemia cells with 5-aza-
2′-dC and the RRM2-inhibitor HU together synergistically 
inhibited cell proliferation and altered DNA methylation 
levels in these cancer cell lines in a dose-dependent man-
ner. These findings suggest RRM2-inhibitors improve the 
demethlyation activity of 5-aza-2′-dC and may have clini-
cal benefit if used in combination.
Our screen utilized a single copy Xi-linked reporter to 
identify the effect of RRM2 inhibition, which was then 
characterized as a genome-wide effect of augmenting 
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5-aza-2′-dC-mediated demethylation. The extension 
of our findings from a single gene reporter on the Xi to 
a genome-wide effect indicates that the Xi can be used 
as a model system for identifying and targeting general 
mechanisms of gene silencing. The optimal dose-sched-
ule of 5-aza-2′-dC remains to be determined and the 
most effective epigenetic therapy will likely require use of 
5-aza-2′ dC in combination with other epigenetic agents 
[40]. The XCR assay may be helpful to accomplish these 
objectives. The robust nature of Xi silencing in differenti-
ated cells, however, contributes to one of the challenges 
of high-throughput screening with this model: XCR is 
partial and occurs at low rates, thus XCR assays must be 
optimized in sensitivity. Previous Xi maintenance screens 
have used pooled shRNA libraries in combination with 
immortalized Xi-GFP transgene-bearing reporter fibro-
blasts [41, 42]. The list of Xi-maintenance candidate fac-
tors from these prior studies is distinct from ours, with 
the exception of Dnmt1, for several potential reasons. 
First, previous approaches did not screen in the presence 
of 5-aza-2′-dC and are thus not expected to find 5-aza-2′-
dC-augmenting pathways such as RRM2-inhibition. Sec-
ond, cell line immortalization has the potential to create 
aberrancies in chromatin silencing pathways that deviate 
from normal development, as in cancer. Therefore, using 
primary MEFs, as in our screen, may more closely reflect 
in  vivo silencing contributions of Xi maintenance path-
ways. However, our single-well format using individual 
siRNAs presents challenges in detecting rare Xi reacti-
vation events, even if adapted to a more sensitive lucif-
erase reporter gene. Our screen was likely underpowered 
to identify novel high-confidence Xi silencing pathways 
as reflected by a low signal-to-noise margin of the assay, 
expressed as a low Z-factor of 0.11 (Additional file  1: 
Figure  S1B). Improvement of the assay using different 
co-treatments (besides 5-aza-2′-dC) to increase rates of 
XCR, may lead to identification of different classes of Xi 
maintenance factors and minimize screening false nega-
tives and positives [43].
Regardless, the adoption of 5-aza-2′-dC in the opti-
mization of this screen in order to sensitize for DNA 
demethylation ultimately led to identification of a 5-aza-
2′-dC-interacting pathway with therapeutic relevance. 
From the standpoint of optimizing epigenetically act-
ing drugs, monitoring gene reactivation from the Xi can 
therefore provide a readout of chromatin reprogramming 
with immediate effects on gene expression.
We used cell proliferation assays and genome-wide 
methylation level estimates in myeloid leukemia cell lines 
to gauge the activity of 5-aza-2′-dC. Our data suggest 
that at a low concentration of 5-aza-2′-dC, the addition of 
low dose HU, increases the fraction of 5-aza-2′-dC that is 
incorporated into DNA and available to inhibit DNMT1. 
This DNA incorporation augmentation effect has the 
potential to represent a therapeutic advantage. RRM2-
inhibitors such as resveratrol and hydroxyurea improve 
the demethylation activity of 5-aza-2′-dC and may have 
clinical benefit if used in combination. The clinical use of 
5-aza-2′-dC is hampered by incomplete disease response 
in AML and MDS and by high rates of adverse effects 
[18, 44, 45]. Its mechanism of action in patients is most 
likely due to a combination of demethylating and direct 
cytotoxic actions that differ in their relative contribution 
according to disease context and 5-aza-2′-dC concen-
tration. At higher doses, 5-aza-2′-dC is thought to form 
DNA adducts leading to DNA synthesis arrest, which 
inhibits its DNA incorporation [20, 46]. Higher doses 
therefore contribute to higher rates of adverse reactions 
including hematologic toxicities [20]. Accordingly, lower 
doses have been favored in more recent clinical trials and 
have shown greater likelihood in eliciting gene expression 
changes as well as producing clinic responses in AML 
and even solid tumors [20, 22, 46]. Thus, increasing DNA 
incorporation of 5-aza-2′-dC at low doses is a promising 
strategy to increase its therapeutic index by biasing its 
activity profile towards DNA demethylation.
In this study, we observed synergistic an anti-prolifera-
tive effect of 5-aza-2′-dC in combination with HU, how-
ever, did not capture genome-wide methylation changes 
at all concentrations to explain this effect. The anti-pro-
liferative effect in the absence of global DNA methylation 
changes is likely secondary to cytotoxic effects such as 
DNA adduct formation and DNA synthesis arrest. Alter-
natively, it is possible that differentially methylated loci 
are preferentially demethylated by 5-aza-2′-dC at lower 
concentrations and expression of these genes drives the 
phenotypic effects of inhibiting proliferation, even when 
mean global methylation levels are not affected.
Previous studies have reported that 5-aza-2′-dC and 
HU drug combination is antagonistic to DNA methyla-
tion based on bisulfite sequencing analysis of three loci 
in two other cancer cell lines [47]. Our data support these 
findings at high concentration HU with 5-aza-2′-dC in 
K562 cells but shows a synergistic effect on DNA dem-
ethylation at lower doses of HU and with RNR inhibi-
tion. The extent of RNR inhibition is likely critical for a 
synergistic interaction with 5-aza-2′-dC as too little RNR 
inhibition will not increase DNA incorporation of 5-aza-
2′-dC and too much RNR inhibition with lead to S-phase 
arrest and interfere with 5-aza-2′-dC-mediated passive 
DNA demethylation (see model Fig. 2a).
Another relevant disease model to test a potential ther-
apeutic benefit of the combination of 5-aza-2′-dC and 
HU may be sickle cell anemia. Current therapies to treat 
the genetic defect in adult hemoglobin are aimed at reac-
tivating the fetal hemoglobin gene [48]. Hydroxyurea is 
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a standard therapy that when administered at cytotoxic 
doses to patients severely affected with sickle cell anemia 
increases fetal hemoglobin levels, but only in a subset of 
patients for unknown reasons [48]. As opposed to mye-
loid leukemia, where the efficacy of 5-aza-2′dC is par-
tially attributable to demethylation, in sickle-cell anemia 
clinical responses to 5-aza-2′-dC do correlate with dem-
ethylation of the fetal hemoglobin gene and increases in 
hemoglobin levels [48–50]. Thus it is appealing to explore 
modified dosing schedules of HU and 5-aza-2′-dC for 
sickle cell patients already receiving these therapies in 
order to potentially exploit some synergistic effect of 
combination therapy for raising hemoglobin levels.
Methods
Genome‑wide siRNA library plate preparation
The Silencer Mouse Druggable siRNA Library V3 and 
Extension set V3 (Ambion) were provided as 250  pmol 
of lyophilized powder in a total of 153 384-well source 
plates, containing one siRNA per well except in columns 
23 and 24, which were reserved for controls. Each of 
21,114 genes is represented by mostly 3 unique (some 2 
unique) siRNAs on different 384-well plates. Plates were 
centrifuged at 1700×g, 50 μl of nuclease-free water was 
added to each well, sealed and briefly vortexed to resus-
pend the siRNAs in individual wells. RNA concentrations 
were confirmed by measuring 1  μl of siRNA solution 
from 14 randomly chosen wells by NanoDrop spectro-
photometer (Thermo Scientific). 2  μl of siRNA diluted 
to 0.5  pmol/μl from each source plate was stamped in 
duplicate onto Matrix white opaque 384-well tissue 
culture-treated plates (Thermo Scientific) by BenchCel 
4X system with a PlateLoc plate sealer, Vcode Barcode 
Printer, and Vprep pipette fitted with a 96 LT head (all 
from Agilent Technologies) and stored in −80°.
Derivation of MEFs
Xi reporter MEFs were derived from a cross between 
transgenic male mice bearing a CAG promoter-driven 
luciferase, H2B-Citrine allele in the Hprt locus, and the 
X-linked GFP, respectively, and transgenic female mice 
heterozygous for an Xist knockout allele [24]. MEFs 
were derived at embryonic day 14.5 and cultured in MEF 
media (DMEM supplemented with 10 % FBS, nonessen-
tial amino acids, l-glutamine, penicillin–streptomycin, 
β-mercaptoethanol) following standard procedures. The 
reporter MEFs with genotypes XiCAG−LuciferaseXaΔXist, 
XiCAG−H2BCitrineXaΔXist, and XiGFPXaΔXist were obtained 
at expected Mendelian ratios of 1 out of 4 embryos and 
identified by PCR genotyping for presence of an Xist 
knockout allele, presence of a FLP-Frt recombination 
production in the Hprt locus and GFP, respectively, and 
lack of Y chromosome gene Zfy [24].
High‑throughput screening siRNA and chemical screening 
assays
The screening assay was optimized to maximize the 
Z-factor statistical measure of signal-to-noise ratio 
between the positive control of Dnmt1 knockdown and 
negative control or no siRNA mock-transfected cells [51]. 
Pilot experiments sequentially tested individual variables 
of the assay such as incubation times and reagent types to 
increase the Z-factor of the assay. The 5-aza-2′-dC con-
centration of 0.2 uM used in the screen was determined 
in this empiric fashion, by titrating a range of 5-aza-2′-dC 
concentrations to determine which would maximally 
increase the signal separation between Dnmt1 knock-
down and control samples, calculated as the Z-factor of 
the assay. The Z-factor of the finalized screening assay 
was 0.11 (Additional file  1: Figure  S1B) [51]. Screen-
ing data analysis was performed by first normalizing 
raw luminescence values by robust z-score which is the 
number of median absolute deviations for a given well 
luminescence value from the plate median luminescence 
value [52].
Primary MEFs from four female Xi-luciferase reporter 
embryos were thawed in 15 cm2 plates, passaged twice at 
a 1:6 split, pooled to ensure a homogeneous cell popu-
lation, and then frozen into 144 vials for use in screen-
ing and hit validation. For the large-scale screen, for 
each batch of 30 plates carrying the genome-wide siRNA 
library, 2 vials of cells were thawed in MEF media. After 
1 day in culture, adherent cells were trypsinized, live cells 
excluding Trypan blue were counted using a hemocy-
tometer and brought up in suspension with MEF media 
agitated by a stir bar.
Meanwhile, a batch of 30 plates including duplicates 
from 15 source plates of 384-well siRNA library were 
thawed at room temperature, centrifuged, and cleaned 
with RNAse-reducing solution (Life Technologies). 
A positive control siRNA targeting Dnmt1 (Ambion 
AM161526) was stamped by BenchCel 4X system with 
an 8 channel LT head (Agilent Technologies) into 16 
wells of column 24 of each library plate by adding 4ul 
of nuclease-free water containing 1 pmol of siDnmt1 to 
each well. The 16 wells of the column 23 were reserved as 
negative control and contained no siRNA. Transfection 
was initiated by adding 20 μl of Opti-MEM (Life Tech-
nologies) and 0.05 μl RNAimax (Life Technologies) per 
well by Multidrop 384 (Thermo Scientific) and incubating 
for 20 min to 1 h. 20 ul of cell suspension containing 2000 
cells with 5-aza-2′-dC (0.4 μM, Sigma) was added to the 
transfection mix, bringing the final 5-aza-2′-dC concen-
tration to 0.2 μM. Cells were incubated for 3  days in a 
humidified 37° incubator at 5 % CO2. 20 μl of media was 
then aspirated off using an ELx 405 plate washer (BioTek 
Instruments) and 20  μl of One-Glo luciferase assay 
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reagent (Promega) was added using the Multidrop 384 
and incubated for 20  min. As luminescence data were 
collected on an Acquest reader (Molecular Devices), 
quality control for each plate was performed by visual 
inspection of positive and negative controls on the heat 
map during data collection.
Chemical screening was performed analogously with 
several exceptions: 384-well plates were not pre-treated. 
Rather, 50  μl of cell suspension with 2000 MEFs and 
5-aza-2′-dC (0.2  μM) were plated in fifteen 384-well 
plates. A positive control mixture was distributed to a 
row of wells on each plate by mixing 50  μl of cell sus-
pension with 2000 cells per well in 1× MEF media with 
high concentration 5-aza-2′-dC (10.0 μM). The screening 
compounds were added to all but positive control wells 
as 0.5 μl of 1 mM stock in DMSO by Biomek FX (Beck-
man Coulter). After 72 h incubation, 30 μl of media were 
aspirated off, and the luciferase assay was performed 
as described for the siRNA screen. Libraries screened 
include 4266 compounds from Microsource (2000), Bio-
mol enzyme inhibitor (337) and bioactive lipid libraries 
(203), Prestwick chemical library (1120), and NIH clinical 
collections (606) at the UCLA MSSR [53]. The 30 chemi-
cals producing highest luciferase values were chosen for 
subsequent validation.
High‑throughput siRNA screening analysis
Genome-wide siRNA screen hits were identified by 
Redundant siRNA Activity (RSA) analysis using robust 
z-scores as the input values [26]. The R script provided by 
Konig et al. was used with minor modifications to adapt 
it for our workflow (http://carrier.gnf.org/publications/
RSA). RSA works by ranking hits in order of activity 
then assigning P values for genes based on whether their 
siRNAs rank higher than would be expected by chance. 
We obtained two activity measurements for each siRNA 
since the siRNA library was screened in duplicate, and 
treated these data points as independent measurements 
with regard to the analysis. Therefore, most genes were 
represented by six data points (and some with four data 
points) in the RSA analysis.
Cell culture and treatment methods
For subsequent Xi-reactivation/validation assays, MEFs 
at passage 1 or 2 post-derivation were seeded at a density 
of 6.0 × 104 cells per 12-well well and chemicals in MEF 
media and/or siRNAs in Opti-MEM media (Gibco) were 
added and incubated for 72  h. For 5-aza-2′-dC (Sigma), 
which was resuspended in DMSO and stored at −80  °C, 
final DMSO concentration on the cells was kept below 
0.1  %. Total volumes of MEF and/or Opti-MEM media 
were normalized across samples when different treatments 
were used. Hydroxyurea and resveratrol (Sigma) were 
resuspended in DMSO and Uridine and Deoxycytidine 
(Sigma) were resuspended in water and stored at −20 °C. 
K562, HL60, U937, and THP1 cells were purchased from 
ATCC. K562, U937, and THP1 cells were cultured in RPMI 
media (Gibco) with 10 % FBS and HL60 cells were cultured 
in IMDM (Gibco) with 20 % FBS. ATCC culture method 
suggestions were followed for expanding the cells. The soft 
agar assay was performed by mixing of 1.2  % nobel agar 
(Sigma) in water with 2X RPMI to achieve final concentra-
tion of 0.6 % agar for the bottom layer. After this solidified 
in 6-well plates, top soft agar was prepared at final 0.3 % 
nobel agar concentration containing K562 cells to achieve 
4.0 × 104 cells per well. DMSO or 5-aza-2′dC (0.05 μM) 
and/or HU (0.05 mM) were added to both bottom and top 
agar layers. This 1000:1 ratio of HU to 5-aza-2′-dC was 
determined to be optimal for the soft agar assay, which is 
different from the 4000:1 optimal ratio used in CellTiter 
Glo assay. Small colonies started appearing 4  days after 
plating. On day 8, colonies were stained with 0.01 % crys-
tal violet for 1  h, washed with PBS, and the plates were 
scanned to obtain images.
Luciferase assay
For each luciferase assay, MEF Xi-luciferase reporter 
treatments were performed in triplicate 12-well wells 
for 72 h and lysed with 200 μl passive lysis buffer (PLB, 
Promega) for 20 min at room temperature on an orbital 
shaker. Lysates were cleared by 30 s of centrifugation and 
20  μl were assayed for luciferase activity with 50  μl of 
LARI reagent (Promega) on a GloMax microplate lumi-
nometer (Promega). Protein concentration measure-
ments were performed on corresponding PLB lysates by 
Quick Start™ Bradford Protein Assay Kit (Bio-Rad) and 
analyzed by interpolating to standard curve according 
to the manufacturer’s instruction. For the proliferation 
assays of leukemia cell lines, 100  μl of well-suspended 
cells were mixed with 100  μl of CellTiter Glo® reagent 
(Promega), incubated at room temperature for 20  min, 
and luciferase units were measured using a GloMax 
microplate luminometer (Promega).
RT‑qPCR analysis
Cells were harvested from a 6-well format in TRI-
zol (Invitrogen) and RNA purification was performed 
with the RNeasy kit (Qiagen) according to manufac-
turer’s instructions with on-column DNAse treatment. 
cDNA was prepared using SuperScript III (Invitrogen) 
with random hexamers and RT-qPCR was performed 
using a M×3000 thermocycler (Stratagene) with prim-
ers for Rrm2 (F-GCACTGGGAAGCTCTGAAAC, 
R-GGCAATTTGGAAGCCATAGA), Dnmt1 (F-CATG 
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AATTCCTGCAAACAGAA, R-TTGACTTTAGCCAG 
GTAGCC), or Gapdh (F- GGCCTTCCGTGTTCCT, 
R-GCCTGCTTCACCACCTTCT). Results were normal-
ized to Gapdh by the ΔCt method.
Knockdowns in follow‑up experiments
Knockdowns by siRNA were performed by reverse trans-
fection at 25 nM final concentration of siRNA. Briefly, a 
cell suspension was added to a pre-incubated mixture of 
Lipofectamine RNAimax, 100 μl of reduced serum Opti-
MEM media, and siRNA. The siRNAs used were Rrm2 
[Ambion, 150659 (A), 64497 (B), 150661 (C)], Dnmt1 
(Ambion, 161526), and, as negative controls, Scramble 
(Ambion, 4636), Luciferase (Dharmacon, D-001210-02), 
Aurkb (Dharmacon, D-063793-01), and GFP (Dhar-
macon, P-002048-01). For Rrm2 knockdown where the 
siRNA is not specified, siRNA 66497 was used.
Flow cytometry
Flow cytometry for measuring the reactivation of the Xi-
linked H2B Citrine and Xi-GFP reporters was performed 
as described previously [24]. For the cell cycle measure-
ment with K526 cells, 5.0  ×  106 cells (determined by 
trypan blue exclusion assay) were taken from each treat-
ment condition, washed once with PBS, and stained with 
propidium iodide buffer (3  mM EDTA pH 8.0, 0.05  % 
NP40, 50 μg/ml PI, 1 mg/ml RNaseA in PBS) for 30 min 
at room temperature. Stained cells were passed through a 
strainer and analyzed by FACSDiva (BD Biosciences) with 
FlowJo software (Tree Star, Inc.).
3H decitabine incorporation
This assay was analogous to the reactivation treatment 
assays with a few modifications: assays were scaled 2.5-
fold to 6-well format, 1 μl (1 μCi) of tritiated 5-aza-2′-dC 
(3H-Decitabine, Moravek Biochemicals Inc.) was added 
instead of cold 5-aza-2′-dC, and samples were harvested 
after 48 h of incubation. Cells were trypsinized, genomic 
DNA isolated using the Quick-gDNA MinPrep kit (Zymo 
Research), and measured by QuBit fluorometer (Life 
Technologies). Tritium content of 25 μl of genomic DNA 
was measured using a scintillation counter and normal-
ized to the measured DNA concentration.
Reduced representation bisulfite sequencing
Primary Xi-reporter MEFs were subjected to the same 
chemical treatment as used for the luciferase assays, 
but in 6-well format, and a fraction of the cells was 
taken to confirm appropriate luciferase reporter activ-
ity. Genomic DNA was isolated using the Blood and 
Cell Culture Mini Kit (Qiagen) with RNase A treat-
ment (Life Technologies). The RRBS libaries were gen-
erated at previously described by Orozco et  al. with 
minor modifications [54]. DNA purifications for each 
enzymatic reaction was carried out using AMPure XP 
beads (Beckman Coulter). Bisulfite conversion was 
performed using the Epitect kit (Qiagen) twice com-
pared to manufacturer’s instruction to optimize the 
efficiency. Bisulfite-converted libraries were amplified 
using MyTaq Mix (Bioline) with the following pro-
gram: (98 °C for 15 s, 60 °C for 30 s, 72 °C for 30 s) 12 
cycles, 72  °C for 5  min, 4  °C storage. DNA Methyla-
tion calling was performed using BS-Seeker2 (2.0.32) 
using Bowtie (0.12.9) for read alignment on the UCLA 
Hoffman2 computer cluster [55]. Reads with adapter 
contamination were trimmed. The adapter sequence 
used for the contamination check was as follows: 
CGAGATCGGAAGAGCACACGTC, i.e. meCG end 
repair ± A tail ±  10 bp of Illumina adapter sequence. 
CpG islands (CGIs) were obtained from UCSC (http://
genome.ucsc.edu) and CGI tracks were based on meth-
ods by Gardiner-Garner and Frommer [56]. Promot-
ers were defined as the region transcription start site 
(TSS) minus 1 kb to TSS for all UCSC genes. Only sites 
covered by at least five reads across all samples under 
consideration were used in an effort to obtain reliable 
methylation levels. The methylation levels of samples 
were hierarchically clustered using complete linkage 
and the Euclidean distance metric. Statistical analysis, 
clustering, and heat map generation were performed 
using custom R scripts [57] (R core team, http://www.r-
project.org).
Public availability of data
All genome-wide data are available from the GEO 
resource at http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE72295.
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Additional files
Additional file 1: Figure S1. Optimization of 5-aza-2’-dC concentration 
for the genome-wide siRNA screen. A. Bar chart illustrating luciferase 
activity from Xi-reporter MEFs upon knockdown of Dnmt1 and treatment 
with varying concentrations of 5-aza-2’-dC in 384-well format for 72 hours. 
Error bars indicate standard deviation from eight measurements in one 
experiment. Aterisks indicate p < 0.01 by Student’s T-test. B. Scatterplot of 
luminescence values from the optimized Xi-reactivation screening assay 
in 384-well format in the presence of 5-aza-2’-dC (0.2 μM) with siDnmt1 
(red) or negative control siAurkb (Aurora kinase B, blue). The Z-factor, a 
measure of separation between positive and negative control populations 
used in the assessment of high-throughput assays, is shown [52].
Additional file 2: Figure S2. Batch effects of genome-wide siRNA 
screening and robust z-score normalization. A. Box plot of all raw 
luciferase measurements distributions per individual 384-well plate from 
one of the duplicates of the siRNA screen. These plates were prepared 
and assayed in 30-plate batches according to their numerical order in 
the source library plates, keeping duplicate plates together. B. As in (A) 
except each measurement was normalized by the robust z-score (median 
absolute deviations from the plate median [52].
Additional file 3: Table S3. Redundant siRNA activity ranking of 
genome-wide siRNA screen data. Table is color-coded to reflect which hit 
genes were validated.
Additional file 4: Figure S3. Validation of gene hits identified by 
genome-wide siRNA screening. The chart displays the luminescence for 
the Xi-luciferase assay in 24-well format with knockdown by the indicated 
siRNAs, chosen as top hits of the genome-wide screen, in combination with 
5-aza-2’-dC (0.2 μM) for 72 hours. For each gene hit, siRNAs were re-ordered 
to match the sequences of the 2 or 3 active siRNA identified by RSA activity 
analysis of the genome-wide siRNA screen. Error bars indicate one standard 
deviation from duplicate wells. siDnmt1 positive control is shown in red.
Additional file 5: Figure S4. Validation of the resveratrol result with 
different Xi-reporter lines. A. Diagram of MEF Xi-H2B Citrine reporter 
genotype. As in Fig. 1A, except the Xi is bearing a CAG-driven histone 
H2B-Citrine reporter gene instead of luciferase in the Hprt locus The chart 
summarizes flow cytometry analysis of Xi-H2B Citrine reporter MEFs 
treated with resveratrol (20 μM) and/or 5-aza-2’-dC (0.2 μM or 10 μM) for 
72 hours. B. Diagram of MEF Xi-GFP reporter genotype. The Xi is bearing a 
randomly integrated CAG-driven GFP allele near the centromere [58]. The 
chart summarizes flow cytometry analysis of GFP reporter MEFs treated 
with siRrm2, resveratrol (20 uM) or HU (0.05 mM), and DMSO or 5-aza-
2’-dC (0.2 μM). Error bars represent standard deviation from triplicate 
wells. C. Representative flow cytometry dot plots of GFP reporter MEFs 
from part B.
Additional file 6: Figure S5. Chemical screen results and validation. A. 
Box plot of all raw luciferase measurements from the chemical screen 
by individual 384-well plate, demonstrating lack of obvious batch effect. 
Chemical library plates were prepared and assayed as one batch of 15 
plates. B. Chart displaying results from the Xi-luciferase assay in the 
24-well format upon treatment with various chemicals (at 10 μM) in the 
presence of 5-aza-2’-dC (0.2 μM) for 72 hours. Error bars indicate one 
standard deviation from duplicate wells except for negative control 5-aza-
2’-dC (0.2 μM) alone (n=16) and positive control 5-aza-2’-dC (10.0 μM) 
alone (n=16). Resveratrol is indicated with an asterisk.
Additional file 7: Figure S6. Protein concentration measurements for 
Xi-luciferase reactivation assays. A. Chart depicts protein concentration of 
cell lysates corresponding to luciferase measurements in (1G). Error bars 
indicate standard deviation from three individual wells. B. As in (A) but 
protein concentrations of cell lysates corresponding to luciferase meas-
urements for (2C). C. As in (A) but protein concentrations of cell lysates 
corresponding to luciferase measurements for (2D).
Additional file 8: Figure S7. Analysis of autosomal DNA methylation in 
MEFs treated with combinations of RNR inhibition and 5-aza-2’-dC. A. (i) 
Heat map of the unsupervised hierarchical clustering as in Fig. 3B but only 
for autosomal CpG sites within CpG islands (CGIs). Genomic locations of 
CpG islands were obtained from UCSC Genome browser (see "Methods" 
section). Constitutively hypermethylated (>0.75) and hypomethylated 
(<0.15) sites were filtered out to improve contrast. (ii) Heat map of the 
unsupervised hierarchical clustering as in Fig. 3B but only for autosomal 
CpG sites within promoters. As in (i), constitutively hypermethylated 
(>0.75) and hypomethylated (<0.15) sites were filtered out to improve 
contrast. Promoters were defined as the region 1 kb upstream of the TSS 
for all UCSC genes. B. Heat maps of the unsupervised hierarchical cluster-
ing as in Fig. 3C for autosomal CpGs within CGIs with at least 5X coverage 
by RRBS across samples, but filtered for sites with methylation levels in 
the untreated sample of either (i) 0.75–1.0 (ii) 0.50–.75 (iii) 0.25–0.50 or (iv) 
0–0.25. C. As in Fig. 3D but for replicate samples. D. Pairwise significance 
test results conducted using a two-sample Kolmogorov-Smirnov test (‘KS-
test stat’ and ‘KS-test p-value’ columns) between the distributions of auto-
somal CpG methylation in Fig. 3D and Figure S7C, as well as two measures 
of effect size: Cohen’s d and the differences between these ‘upper modes’ 
between the comparisons (‘Delta upper mode’ column).
Additional file 9: Figure S8. Analysis of DNA methylation status on the 
X chromosome in MEFs treated with combinations of RNR inhibition and 
5-aza-2’-dC. A. Heat map of the unsupervised hierarchical clustering of 
CpG methylation levels in MEFs as in Fig. 3B, except that the data for X 
chromosome CpG sites are shown. B. (i) Heat map of the unsupervised 
hierarchical clustering as in Fig. 3B but only for CpG sites within CpG 
islands on the X chromosome. Constitutively hypermethylated (>0.75) and 
hypomethylated (<0.15) sites were filtered out to improve contrast. (ii) As 
in (i) except for CpG sites within promoters on the X chromosome. Again, 
constitutively hypermethylated (>0.75) and hypomethylated (<0.15) sites 
were filtered out to improve contrast. Promoters were defined as the 
region 1 kb upstream of the TSS for all UCSC genes.
Additional file 10: Figure S9. DNA methylation status of the luciferase 
transgene in MEFs treated with combinations of RNR inhibition and 
5-aza-2’-dC. A. Bar chart displaying average CpG methylation levels for the 
indicated treatments filtered by CpGs with at least 5X sequencing cover-
age by RRBS across all samples as in Fig. 3A, but only considering the CpGs 
in the luciferase reporter gene/promoter. B. Heat map of unsupervised 
hierarchical clustering of CpG methylation levels as in Fig. 3B except for 
CpG sites in the luciferase reporter gene/promoter. C. As in (B), except for 
CpG sites within the luciferase reporter with a methylation level greater 
than 0.75 in both of the untreated samples. D. Histograms showing the 
distribution of CpG methylation levels within the luciferase reporter gene.
Additional file 11: Figure S10. Synergistic effect of HU and 5-aza-2’dC 
on myeloid leukemia cell line proliferation. A. Graphs represent cell counts 
measured with the hemocytometer after trypan blue staining compared 
to viable cell number measurement determined by CellTiter-Glo reagent 
(Promega) for four myeloid leukemia cell lines. High correlation coefficient, 
R2, demonstrates linear relationship. B. Dose response curves as in Fig. 4A, 
except for THP1 cells using a fixed concentration ratio of 1000:1 HU:Aza. 
C. Dose response curves as in Fig. 4A, except for U937 cells using a fixed 
concentration ratio of 300:1 HU:Aza. D. Soft agar assay of K562 cells plated 
in DMSO or 5-aza-2’dC (0.05 uM) and/or HU (0.05 mM) in a final concentra-
tion of 3% agar and stained with crystal violet after 8 days of growth.
Additional file 12: Figure S11. Extended data on the methylation 
analysis of K562 cells. A. Heat map showing an unsupervised hierarchical 
clustering of X chromosome CpG methylation in K562 cells treated with 
the indicated chemicals for 72 hours as in Fig. 4C but for all X chromo-
some CpGs. B. CpG methylation distribution along the X chromosome in 
K562 cells, for CpG sites with at least 10X coverage across all samples as 
determined by RRBS. Chemical treatments are as shown in Fig. 4A/C.
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